AKR1C4抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-2: A549 cell lysate and Human fetal liver tissue lysate, Primary antibody: P08417(AKR1C4 Antibody) at dilution 1/250, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 3 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P08417(AKR1C4 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

The AKR1C4 antibody is designed to target the aldo-keto reductase family 1 member C4 (AKR1C4), an enzyme belonging to the AKR superfamily. This enzyme plays a role in metabolizing steroids, prostaglandins, and xenobiotics, primarily functioning as a reductase in steroid hormone regulation, particularly in the liver and reproductive tissues. AKR1C4 is involved in the conversion of potent androgens and estrogens into less active forms, influencing hormone-dependent physiological processes and diseases.

Research on AKR1C4 has implications in understanding endocrine disorders, cancers (e.g., hormone-sensitive tumors), and drug metabolism. The AKR1C4 antibody is a critical tool for detecting and quantifying protein expression in tissues or cell lines via techniques like Western blotting, immunohistochemistry, or immunofluorescence. It helps elucidate the enzyme's tissue distribution, expression levels under pathological conditions, and interactions with substrates or inhibitors.

Antibody specificity is validated using knockdown controls or recombinant protein assays. Researchers also employ it to study AKR1C4's role in metabolic pathways, such as its interplay with other AKR isoforms or its impact on steroid hormone balance. Challenges include cross-reactivity with homologous AKR family members, necessitating careful experimental design. Overall, the AKR1C4 antibody advances studies in endocrinology, oncology, and toxicology, bridging molecular insights with clinical applications.